Protagonist Therapeutics (NASDAQ:PTGX) Director Sells $896,760.00 in Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director William Waddill sold 9,000 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $99.64, for a total transaction of $896,760.00. Following the completion of the sale, the director directly owned 7,825 shares of the company’s stock, valued at approximately $779,683. This trade represents a 53.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Protagonist Therapeutics Price Performance

Shares of PTGX opened at $95.41 on Thursday. Protagonist Therapeutics, Inc. has a 1-year low of $49.38 and a 1-year high of $107.84. The stock has a market cap of $6.14 billion, a PE ratio of -52.71 and a beta of 1.85. The firm has a fifty day moving average price of $101.42 and a 200 day moving average price of $92.32.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.55. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. The firm had revenue of $56.37 million during the quarter, compared to analysts’ expectations of $11.70 million. As a group, equities analysts expect that Protagonist Therapeutics, Inc. will post 3.29 EPS for the current fiscal year.

Analysts Set New Price Targets

PTGX has been the subject of a number of research reports. Leerink Partners boosted their price target on shares of Protagonist Therapeutics from $107.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. Wolfe Research initiated coverage on shares of Protagonist Therapeutics in a research note on Thursday, May 21st. They issued an “outperform” rating and a $135.00 price objective on the stock. TD Cowen lifted their price objective on shares of Protagonist Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. JPMorgan Chase & Co. lifted their price objective on shares of Protagonist Therapeutics from $95.00 to $106.00 and gave the company an “overweight” rating in a research note on Thursday, March 19th. Finally, Wedbush lifted their price objective on shares of Protagonist Therapeutics from $112.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $115.21.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Farther Finance Advisors LLC increased its stake in Protagonist Therapeutics by 110.6% in the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after purchasing an additional 156 shares during the period. Greenline Wealth Management LLC acquired a new position in Protagonist Therapeutics in the fourth quarter valued at $27,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Protagonist Therapeutics by 138.9% in the third quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock valued at $36,000 after acquiring an additional 314 shares in the last quarter. Abich Financial Wealth Management LLC purchased a new stake in shares of Protagonist Therapeutics in the third quarter valued at about $62,000. Finally, Hantz Financial Services Inc. boosted its holdings in shares of Protagonist Therapeutics by 222.4% in the fourth quarter. Hantz Financial Services Inc. now owns 951 shares of the company’s stock valued at $83,000 after acquiring an additional 656 shares in the last quarter. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.